Manufacturer Rebate Summary Report
2014 Part D Rebate Summary for All Brand Name Drugs
| Total Brand Name Drug Rebate1 | Total Brand Name Drug Cost2 | Rebate % (of Total Brand Name Drug Cost) |
| $16,268,249,791 | $92,954,130,307 | 17.5% |
2014 Part D Brand Name Drug Rebate Summary by Therapeutic Class3
| Drug Class3 | Total Brand Name Drug Rebate1 | Total Brand Name Drug Cost2 | Rebate % (of Class Total Brand Name Drug Cost) |
| Cardiovascular Drugs | $2,868,830,328 | $10,890,974,066 | 26.3% |
| Central Nervous System Agents | $1,959,659,465 | $15,042,684,392 | 13.0% |
| Hormones and Synthetic Substitutes | $5,129,689,466 | $20,532,619,261 | 25.0% |
| Miscellaneous Therapeutic Agents | $1,177,101,010 | $12,650,285,884 | 9.3% |
| All Other Classes | $7,118,633,721 | $46,835,503,748 | 15.2% |
2014 Part D Rebate Summary for Brand Name Drugs in Medicare Drug Spending Dashboard
| Total Brand Name Drug Rebate1 | Total Brand Name Drug Cost2 | Rebate % (of Total Brand Name Drug Cost) |
| $6,594,230,823 | $37,098,203,804 | 17.8% |
1 Restricted to rebates associated with Part D drug events in calendar year 2014. Excludes non-rebate amounts reported as "other direct and indirect remuneration."
2 Based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.
3 Drug classes based on the American Hospital Formulary System (AHFS) level 2 drug categories. These classes were chosen due to their broad inclusion of many drugs and many manufacturers. A small number of drugs are included in multiple classes (e.g., combination drugs), thus class-level totals do not sum to the grand total.
Page Last Modified:
09/06/2023 04:51 PM